NASDAQ:BFRI Biofrontera (BFRI) Stock Forecast, Price & News $0.46 0.00 (0.00%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$0.46▼$0.4950-Day Range$0.40▼$0.6552-Week Range$0.37▼$2.86Volume11,896 shsAverage Volume122,623 shsMarket Capitalization$12.42 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Biofrontera MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,405.4% Upside$7.00 Price TargetShort InterestHealthy1.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.25Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.79) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector1003rd out of 1,980 stocksPharmaceutical Preparations Industry485th out of 978 stocks 3.5 Analyst's Opinion Consensus RatingBiofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Biofrontera has a forecasted upside of 1,405.4% from its current price of $0.47.Amount of Analyst CoverageBiofrontera has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.76% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently increased by 12.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BFRI. Previous Next 2.1 News and Social Media Coverage News SentimentBiofrontera has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Biofrontera this week, compared to 1 article on an average week.Search Interest6 people have searched for BFRI on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows1 people have added Biofrontera to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Biofrontera is held by insiders.Percentage Held by InstitutionsOnly 6.84% of the stock of Biofrontera is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Biofrontera are expected to grow in the coming year, from ($0.79) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biofrontera is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biofrontera is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiofrontera has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biofrontera (NASDAQ:BFRI) StockBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.Read More Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address BFRI Stock News HeadlinesJune 1, 2023 | finanznachrichten.deBiofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz-PDTMay 30, 2023 | finance.yahoo.comBiofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive OfficerJune 2, 2023 | Edge On The Street (Ad)How to Invest in AI's Fast-Growing MarketThe AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.May 15, 2023 | finance.yahoo.comBiofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side EffectsMay 12, 2023 | finance.yahoo.comBiofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2023 | msn.comBiofrontera reports misses Q1 top and bottom consensus; reaffirms FY23 outlookMay 12, 2023 | finance.yahoo.comBiofrontera Inc. Announces Resignation of CEOMay 12, 2023 | finance.yahoo.comBiofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business UpdateJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 10, 2023 | americanbankingnews.comBiofrontera (BFRI) to Release Earnings on FridayMay 9, 2023 | finance.yahoo.comBiofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer PreventionApril 28, 2023 | finance.yahoo.comBiofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023April 26, 2023 | finance.yahoo.comBiofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)April 20, 2023 | americanbankingnews.comReviewing Clever Leaves (NASDAQ:CLVR) & Biofrontera (NASDAQ:BFRI)April 3, 2023 | nasdaq.comBiofrontera Inc. Common Stock (BFRI)March 27, 2023 | finance.yahoo.comBiofrontera Inc. Makes Transformative Investment in Its' Dermatology SalesforceMarch 17, 2023 | finance.yahoo.comBiofrontera Inc. to Attend 2023 American Academy of Dermatology Annual MeetingMarch 11, 2023 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI) Analysts Just Slashed Next Year's EstimatesMarch 10, 2023 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | finance.yahoo.comCORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial ResultsMarch 8, 2023 | finance.yahoo.comBiofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial ResultsMarch 2, 2023 | finance.yahoo.comBiofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023February 22, 2023 | finance.yahoo.comBiofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023February 15, 2023 | finance.yahoo.comBiofrontera, Inc. to Present at Third Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 21st – 24th, 2023January 24, 2023 | finance.yahoo.comBreakeven On The Horizon For Biofrontera Inc. (NASDAQ:BFRI)January 9, 2023 | finance.yahoo.comBiofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and TrunkJanuary 9, 2023 | finance.yahoo.comBiofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022See More Headlines BFRI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BFRI Company Calendar Last Earnings3/13/2023Today6/01/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BFRI CUSIPN/A CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+1,405.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-640,000.00 Net Margins-49.46% Pretax Margin-49.44% Return on Equity-109.94% Return on Assets-43.89% Debt Debt-to-Equity RatioN/A Current Ratio1.82 Quick Ratio1.49 Sales & Book Value Annual Sales$28.67 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.74Miscellaneous Outstanding Shares26,700,000Free Float26,528,000Market Cap$12.42 million OptionableNot Optionable Beta0.95 Key ExecutivesDr. Hermann Lubbert Ph.D. (Age 67)Exec. Chairman & Pres Comp: $18.02kMs. Erica L. Monaco CPA (Age 38)CEO, COO, Treasurer & Sec. Comp: $402.12kMr. Eugene Fredrick Leffler III (Age 39)Chief Financial Officer Ms. Erica F. Gates CPAM.B.A., Sr. Director of Fin. & Principal Accounting OfficerMs. Alycia TorresVP of Admin.Mr. Daniel Hakansson J.D.Gen. Counsel & Head of ComplianceMr. Mark BaldygaHead of Sales & MarketingMr. Jeff HolmHead of Professional Relations & Commercial Devel.More ExecutivesKey CompetitorsFrequency TherapeuticsNASDAQ:FREQTrevenaNASDAQ:TRVNNanoViricidesNYSE:NNVCComera Life SciencesNASDAQ:CMRABio-PathNASDAQ:BPTHView All Competitors BFRI Stock - Frequently Asked Questions Should I buy or sell Biofrontera stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BFRI shares. View BFRI analyst ratings or view top-rated stocks. What is Biofrontera's stock price forecast for 2023? 1 Wall Street research analysts have issued twelve-month target prices for Biofrontera's stock. Their BFRI share price forecasts range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,405.4% from the stock's current price. View analysts price targets for BFRI or view top-rated stocks among Wall Street analysts. How have BFRI shares performed in 2023? Biofrontera's stock was trading at $0.9166 at the beginning of the year. Since then, BFRI stock has decreased by 49.3% and is now trading at $0.4650. View the best growth stocks for 2023 here. Are investors shorting Biofrontera? Biofrontera saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 270,800 shares, an increase of 12.3% from the April 30th total of 241,200 shares. Based on an average trading volume of 95,100 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.8% of the shares of the company are short sold. View Biofrontera's Short Interest. When is Biofrontera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our BFRI earnings forecast. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) released its earnings results on Monday, March, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The company earned $10.14 million during the quarter, compared to analysts' expectations of $10.32 million. Biofrontera had a negative trailing twelve-month return on equity of 109.94% and a negative net margin of 49.46%. What guidance has Biofrontera issued on next quarter's earnings? Biofrontera issued an update on its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $35.84M-, compared to the consensus revenue estimate of $36.50 million. When did Biofrontera IPO? (BFRI) raised $19 million in an IPO on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO. What is Biofrontera's stock symbol? Biofrontera trades on the NASDAQ under the ticker symbol "BFRI." How do I buy shares of Biofrontera? Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biofrontera's stock price today? One share of BFRI stock can currently be purchased for approximately $0.47. How much money does Biofrontera make? Biofrontera (NASDAQ:BFRI) has a market capitalization of $12.42 million and generates $28.67 million in revenue each year. The company earns $-640,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. How can I contact Biofrontera? The official website for the company is www.biofrontera-us.com. The company can be reached via phone at 781-245-1325 or via email at us-ir@biofrontera.com. This page (NASDAQ:BFRI) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.